• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Fondaparinux: Better than Enoxaparin for Patients with Acute Coronary Syndromes?

  • in Cardiovascular · ESC 2005
  • — 12 Sep, 2005
Fondaparinux: Better than Enoxaparin for Patients with Acute Coronary Syndromes?
AudioMedica News
Fondaparinux: Better than Enoxaparin for Patients with Acute Coronary Syndromes?
Fondaparinux: Better than Enoxaparin for Patients with Acute Coronary Syndromes?
00:00 /
RSS Feed
Share
Link
Embed
//-->//>' class="input-embed input-embed-61"/>
Freek Verheugt
Freek Verheugt

Shamir Mehta of McMaster University told Audio Medica in Stockholm about the OASIS-5/MICHELANGELO results comparing the new anti-thrombotic therapy, fondaparinux, with enoxaparin among patients with acute coronary syndromes. For a comment on Shamir Mehta’s presentation at the ESC meeting, Audio Medica questioned Freek Verheugt of Nijmegen.
Shamir Mehta: [audio:https://www.audiomedica.com/podcasting/08.Shamir_Mehta.mp3] Freek Verheugt: [audio:https://www.audiomedica.com/podcasting/09.Freek_Verheugt.mp3]

Click here for all the interviews from ESC 2005

You may also like...

  • Optimized Anti-Platelet Therapy Avoids Stent Thrombosis With Drug Eluting Stents: HORIZON-AMI Trial Results Optimized Anti-Platelet Therapy Avoids Stent Thrombosis With Drug Eluting Stents: HORIZON-AMI Trial Results 31 Mar, 2009
  • Aging signs predict coronary risk independently of chronological age Aging signs predict coronary risk independently of chronological age 31 Dec, 2012
  • Intensive Glycaemic Control: Meta Analysis Confirms Benefit In Type II Diabetes Intensive Glycaemic Control: Meta Analysis Confirms Benefit In Type II Diabetes 23 Jun, 2009
  • REPAIR-AMI: Progenitor Cells Regenerate the Heart after Infarction REPAIR-AMI: Progenitor Cells Regenerate the Heart after Infarction 16 Nov, 2005

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Previous story Audio Journal of Oncology 13.3, April 2005
  • Next story Drug-eluting Stents: Cost-Benefit Targeting?
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Microbiome Diversity Key To Survival After…
    • Ibrutinib: New Frontline Standard for Chronic…
    • Genomic-led AML Clinical Decision Making Within Seven Days
    • Childhood Obesity—Whose Business Is It?
    • New Front Line Standard for Older Patients with…
  • Home
  • Cardiovascular
  • Fondaparinux: Better than Enoxaparin for Patients with Acute Coronary Syndromes?

© COPYRIGHT 2020 AUDIOMEDICA.COM.